GW501516: The Controversial Compound Shaping the Future
GW501516, is a synthetic PPARδ agonist developed in the 1990s for obesity and cardiovascular applications. Its ability to enhance endurance and fat loss garnered interest in bodybuilding. Yet, safety issues halted its approval, citing cancer risks in animal studies. Banned by WADA, it remains controversial regarding efficacy and safety.

